📣 VC round data is live. Check it out!
- Public Comps
- Myomo
Myomo Valuation Multiples
Discover revenue and EBITDA valuation multiples for Myomo and similar public comparables like Vivos, BrainCool, Q-linea, Spirit Scientific Co and more.
Myomo Overview
About Myomo
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Founded
2004
HQ

Employees
185
Website
Financials (LTM)
EV
$33M
Valuation Multiples
Start free trialMyomo Financials
Myomo reported last 12-month revenue of $42M and negative EBITDA of ($11M).
In the same LTM period, Myomo generated $28M in gross profit, ($11M) in EBITDA losses, and had net loss of ($15M).
Revenue (LTM)
Myomo P&L
In the most recent fiscal year, Myomo reported revenue of $41M and EBITDA of ($11M).
Myomo is unprofitable as of last fiscal year, with gross margin of 66%, EBITDA margin of (28%), and net margin of (38%).
Financial data powered by Morningstar, Inc.
Myomo Stock Performance
Myomo has current market cap of $30M, and enterprise value of $33M.
Market Cap Evolution
Myomo's stock price is $0.78.
Myomo share price decreased by 9.5% in the last 30 days, and by 73.8% in the last year.
Myomo has an EPS (earnings per share) of $-0.40.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $33M | $30M | -8.4% | -9.5% | 0.4% | -73.8% | $-0.40 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMyomo Valuation Multiples
Myomo trades at 0.8x EV/Revenue multiple, and (3.1x) EV/EBITDA.
EV / Revenue (LTM)
Myomo Financial Valuation Multiples
As of May 13, 2026, Myomo has market cap of $30M and EV of $33M.
Myomo has a P/E ratio of (2.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Myomo Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Myomo Margins & Growth Rates
Myomo grew revenue by 9% but EBITDA decreased by 18% in the last fiscal year.
In the most recent fiscal year, Myomo reported gross margin of 66%, EBITDA margin of (28%), and net margin of (38%).
Myomo Margins
Myomo Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Myomo Operational KPIs
Myomo's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Myomo's Rule of 40 is (13%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Myomo's Rule of X is 0% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Myomo Competitors
Myomo competitors include Vivos, BrainCool, Q-linea, Spirit Scientific Co, Polyrizon, AnteoTech, CS Diagnostics, Genematrix, Finemedix and Genomtec.
Most Myomo public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 441.3x | — | (9.5x) | — | |||
| 6.8x | 6.6x | (8.1x) | (9.3x) | |||
| 6.6x | — | (0.5x) | — | |||
| 2.3x | — | 11.0x | — | |||
| — | — | (5.3x) | — | |||
| 40.1x | 43.3x | (7.6x) | (11.6x) | |||
| — | — | 384.9x | — | |||
| 2.7x | — | (24.6x) | — | |||
This data is available for Pro users. Sign up to see all Myomo competitors and their valuation data. Start Free Trial | ||||||
Myomo Funding History
Before going public, Myomo raised $12M in total equity funding, across 2 rounds.
Myomo Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Myomo
| When was Myomo founded? | Myomo was founded in 2004. |
| Where is Myomo headquartered? | Myomo is headquartered in United States. |
| How many employees does Myomo have? | As of today, Myomo has over 185 employees. |
| Who is the CEO of Myomo? | Myomo's CEO is Paul R. Gudonis. |
| Is Myomo publicly listed? | Yes, Myomo is a public company listed on NYSE American. |
| What is the stock symbol of Myomo? | Myomo trades under MYO ticker. |
| When did Myomo go public? | Myomo went public in 2017. |
| Who are competitors of Myomo? | Myomo main competitors include Vivos, BrainCool, Q-linea, Spirit Scientific Co, Polyrizon, AnteoTech, CS Diagnostics, Genematrix, Finemedix, Genomtec. |
| What is the current market cap of Myomo? | Myomo's current market cap is $30M. |
| What is the current revenue of Myomo? | Myomo's last 12 months revenue is $42M. |
| What is the current revenue growth of Myomo? | Myomo revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Myomo? | Current revenue multiple of Myomo is 0.8x. |
| Is Myomo profitable? | No, Myomo is not profitable. |
| What is the current EBITDA of Myomo? | Myomo has negative EBITDA and is not profitable. |
| What is Myomo's EBITDA margin? | Myomo's last 12 months EBITDA margin is (25%). |
| What is the current EV/EBITDA multiple of Myomo? | Current EBITDA multiple of Myomo is (3.1x). |
| What is the current FCF of Myomo? | Myomo's last 12 months FCF is ($16M). |
| What is Myomo's FCF margin? | Myomo's last 12 months FCF margin is (39%). |
| What is the current EV/FCF multiple of Myomo? | Current FCF multiple of Myomo is (2.1x). |
| How many companies Myomo has acquired to date? | Myomo hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Myomo has invested to date? | Myomo hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Myomo
Lists including Myomo
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.